featured
Long-Term Follow-Up of Chemoimmunotherapy With Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone in Patients With Relapsed CD20+ B-Cell NHL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Follow-Up of Chemoimmunotherapy With Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkin Lymphoma: Results of a Study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 Now Known as Academic and Community Cancer Research United (ACCRU)
Am. J. Hematol 2017 Jun 14;[EPub Ahead of Print], TE Witzig, PB Johnston, BR LaPlant, PJ Kurtin, LD Pederson, DF Moore, NH Nabbout, DA Nikcevich, KM Rowland, A GrotheyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.